06/04/2026
AbbVie's Allergan Aesthetics division reported a 6.1% revenue decline in 2025, falling from $5.18B to $4.86B globally.
What does this mean for dermatology practice owners?
In today's market, buyers aren't just evaluating growth. They're evaluating stability. Practices with a balanced mix of medical and aesthetic dermatology are proving more resilient, while those heavily reliant on cash-pay aesthetics face increased scrutiny.
Aesthetic services remain an important profitability driver, but as demand normalizes, diversification is becoming a key factor in valuation.
Read the full Q2 2026 Dermatology M&A Market Report: https://hubs.li/Q04kc8RS0